A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Phase 4 Active not recruiting 23 enrolled Kyowa Kirin Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of mogamulizumab (KW-0761) in chinese subjects with mycosis fungoides or sézary syndrome previously treated with systemic therapy

Timeline

Start: 2023-05-29
Primary completion: 2025-08-12
Completion: 2025-11-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mogamulizumab	Monoclonal antibody	1 mg/kg	Intravenous

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

Summary

Timeline

Drugs

Indications